Navigation Links
Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimer's Disease Program
Date:11/15/2013

Disease (AD)
Alzheimer's disease is a progressive disorder of the brain that gradually affects one's memory and ability to learn, reason, communicate and carry out daily activities. There are now more than five million people in the United States living with AD, and there is currently no cure.

About CTAD
Since 2008, CTAD has been a conference organized and planned by AD clinical researchers for AD clinical researchers. CTAD embraces the organizing committee mandate to maintain CTAD's unique role in AD research: To provide a substantive, clinical research-oriented conference and an annual opportunity for the world's preeminent clinical researchers to engage in both formal and informal exchanges of views. CTAD's ongoing commitment to providing a relatively intimate forum has resulted in the conference's reputation of facilitating and fostering international collaboration in AD clinical research matters. More information is available at www.ctad-alzheimer.com.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
2. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
3. Sangamo BioSciences Proposes Public Offering Of Common Stock
4. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
5. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
6. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
7. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
8. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
9. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 Psyche Systems ... alliance which offers a first-of-its-kind platform that helps labs ... to lab results, transforms the way patients engage with ... Luminate Health provides a HIPAA-compliant digital platform ... access, manage, and understand their lab results, and uniquely ...
(Date:5/5/2015)... May 5, 2015  Renova™ Therapeutics, a biopharmaceutical ... failure and other chronic diseases, has engaged RAND ... designed to reflect the healthcare patterns of multiple ... will be used to characterize the impact the ... on those groups of patients and the overall ...
(Date:5/5/2015)... 5, 2015  A group of biotechnology executives and ... Research Institute, a non-profit organization dedicated to providing education, ... from disorders of consciousness.  ... ... which no voluntary actions can be initiated by the ...
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing ... - Global Version" report to their offering. ... area of molecular diagnostics and pharmacogenics hold the ... market that is moving out of the national ...
Breaking Biology Technology:Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... Dec. 27 The "Clinical and Economical,Considerations For ... by,Industry Expert Richard Rosenfeld, RPh, MBA, for Baxa ... for media and,professional reference. The paper is an ... a model for implementation of a successful,program., ...
... SEATTLE, Dec. 26 Cell Therapeutics, Inc.,(CTI) (Nasdaq and ... December 27) at 8:30 am EST to discuss update ... results., Conference Call Numbers Thursday, December ... Pacific 800-218-0204 303-262-2130, Webcast available at ...
... Md., Dec. 26 Sirnaomics, Inc. announced,today ... a variety of Government,Programs. Sirnaomics, Inc. ... 2007, dedicates to advancing RNA interference,(RNAi) Technology ... The company,s multi-targeted siRNA therapeutic programs and,its ...
Cached Biology Technology:'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use 2Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs 2Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs 3
(Date:4/27/2015)... Conn. , Apr. 27, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... commence shipping to pre-order customers the first week of ... through the month of May. ... a significant milestone for the company as Wocket® enters ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... this study, carried out in collaboration with the University of ... the US) is to characterize some aspects of gastropod (snails ... To what extent do they depend on the physical properties ... fundamental when applying the studied mechanism to the construction of ...
... Research continues to show that the controversial abortion drug ... besides hysterectomy for women who suffer from severe symptoms ... Medical Center in 2004 began investigating mifepristone, in a ... to treat fibroids, which affect roughly half of all ...
... D.C. (March 7, 2011) -- All our daily activities, from ... signals carried along the body,s vast network of neurons. Propagation ... molecules within nerve cells -- receptors, ion channels, and transmitters ... the study of these molecules in real time has not ...
Cached Biology News:A study reveals the keys to the locomotion of snails 2A study reveals the keys to the locomotion of snails 3Pathology study tracks uterine changes with mifepristone 2Pathology study tracks uterine changes with mifepristone 3
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... serum is collected off the clot from fasted Cynomolgus ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA ... N-07: CPD N-09: K3EDTA ...
adult...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: